Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

205.02 +3.12 (+1.55%)
Streaming Delayed Price Updated: 1:41 PM EDT, Mar 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Janssen Scores Conditional Approval For Multiple Myeloma Treatment In Pretreated Patients ↗
 
Via Benzinga
News headline image
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
On Wednesday, 348 companies hit new 52-week lows. Significant Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was... 
Via Benzinga
News headline image
Earnings Scheduled For February 17, 2022 ↗
Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million. 
Via Benzinga
News headline image
Ligand Pharmaceuticals: Q2 Earnings Insights ↗
  Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q2 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Ligand Pharmaceuticals... 
Via Benzinga
News headline image
Ligand Reports Second Quarter 2022 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Report Second Quarter Financial Results on August 8
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Barclays Maintains Overweight Rating for Ligand Pharmaceuticals: Here's What You Need To Know ↗
Barclays has decided to maintain its Overweight rating of Ligand Pharmaceuticals (NASDAQ:LGND) and lower its price target from $165.00 to $157.00. Shares of Ligand Pharmaceuticals are trading up 1.79%... 
Via Benzinga
News headline image
Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
10 Biggest Price Target Changes For Monday ↗
Needham cut the price target on Carvana Co. (NYSE: CVNA) from $121 to $80. Carvana shares rose 11.3% to $42.71 in pre-market trading. 
Via Benzinga
News headline image
Ligand Reports First Quarter 2022 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Report First Quarter Financial Results on May 4
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Ligand To Spin-Off OmniAb Via Avista Capital-Backed SPAC Merger ↗
Ligand Pharmaceuticals Inc (NASDAQ: LGND)  
Via Benzinga
News headline image
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Tough Slogging Ahead for Investors, Diversification is Important ↗
Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows. 
Via Talk Markets
News headline image
Recap: Ligand Pharmaceuticals Q4 Earnings ↗
Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Ligand Reports Fourth Quarter and Full Year 2021 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More ↗
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news... 
Via Benzinga
News headline image
Ligand to Report Fourth Quarter Financial Results on February 17
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand and GSK Expand Global Collaboration and License Agreement
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Meme Stock Breakdown ↗
There have been plenty of market happenings and themes in 2021 but perhaps one of the more intriguing ones was the recurring bouts of meme stock mania. 
Via Talk Markets
News headline image
Ligand Pharmaceuticals Sees RS Rating Rise To 92 ↗
A Relative Strength Rating upgrade for Ligand Pharmaceuticals shows improving technical performance. 
Via Investor's Business Daily
News headline image
Ligand To Spin-Off OmniAb Platform Into Its Own Independent Company ↗
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced plans to split into two separate publicly traded companies. One company will feature the OmniAb... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.